Argos Therapeutics Inc. (NASDAQ:ARGS) has received an average recommendation of “Buy” from the eight research firms that are covering the firm. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $12.43.

Several equities analysts have recently issued reports on ARGS shares. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Friday, June 17th. Piper Jaffray Cos. restated an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Monday, June 20th. Zacks Investment Research lowered Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, FBR & Co decreased their price objective on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th.

In other news, major shareholder International S. Pharmstandard purchased 67,371 shares of Argos Therapeutics stock in a transaction on Wednesday, August 24th. The stock was purchased at an average price of $4.52 per share, with a total value of $304,516.92. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder International S. Pharmstandard purchased 43,618 shares of Argos Therapeutics stock in a transaction on Thursday, September 29th. The shares were purchased at an average cost of $4.56 per share, with a total value of $198,898.08. The disclosure for this purchase can be found here. Company insiders own 61.64% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ARGS. Schwab Charles Investment Management Inc. purchased a new position in Argos Therapeutics during the second quarter worth $137,000. California State Teachers Retirement System purchased a new position in Argos Therapeutics during the second quarter worth $137,000. KCG Holdings Inc. purchased a new position in Argos Therapeutics during the second quarter worth $163,000. BlackRock Investment Management LLC increased its position in Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the period. Finally, Geode Capital Management LLC increased its position in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the period. 11.05% of the stock is owned by hedge funds and other institutional investors.

Argos Therapeutics (NASDAQ:ARGS) opened at 4.70 on Monday. Argos Therapeutics has a 52-week low of $1.61 and a 52-week high of $13.97. The stock has a 50 day moving average of $4.89 and a 200-day moving average of $5.91. The company’s market cap is $193.62 million.

Argos Therapeutics (NASDAQ:ARGS) last posted its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, analysts forecast that Argos Therapeutics will post ($1.56) EPS for the current year.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.